Home › Morbo di Parkinson › Connecticut › New Haven
Studi clinici su Morbo di Parkinson a New Haven, CT
14 studi su Morbo di Parkinson cercano partecipanti presso sedi a New Haven e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
In reclutamentoFase 1Volontari sani benvenuti
- XingImaging LLC, New Haven
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
In reclutamentoFase 2/3
- Site-028, New Haven
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
In reclutamentoFase 2
- Yale University, New Haven
This Protocol is a Sub-study Under the PPMI Program. It is a Longitudinal, Single-center Study to Assess the Performance of [18F]AV-133 Imaging Using High and Standard Resolution PET in Individuals Enrolled With Parkinson's Disease (PD) for up to 12 Months.
In reclutamentoFase 2Volontari sani benvenuti
- Institute for Neurodegenerative Disorders, New Haven
A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications
In reclutamentoStudio osservazionale
- Yale School of Medicine's Stephen and Denise Adams Center for Parkinson's Disease Research, New Haven
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
In reclutamentoFase 3
- Institute for Neurodegenerative Disorders, New Haven
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
In reclutamentoFase 2Volontari sani benvenuti
- Institute for Neurodegenerative Disorders / XingImaging, LLC, New Haven
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Institute For Neurodegenerative Disorders, New Haven
Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
In reclutamentoFase 1 inizialeVolontari sani benvenuti
- Institute for Neurodegenerative Disorders and XingImaging, LLC, New Haven
Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers
In reclutamentoFase 1 inizialeVolontari sani benvenuti
- Institute for Neurodegenerative Disorders and XingImaging, LLC, New Haven
Intestinal Immunity in Neurologic Disease
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Yale MS Clinic, North Haven · a 7 mi di distanza
Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503
In reclutamentoFase 1 inizialeVolontari sani benvenuti
- Yale New Haven Hospital, New Haven
Imaging Depression in Parkinson's Disease
In reclutamentoFase 2Volontari sani benvenuti
- Yale University, New Haven
Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder
In reclutamentoStudio osservazionale
- Digestive Disease Associates, Branford · a 6 mi di distanza
Studi su Morbo di Parkinson in altre città
- New York City, NY23 studi
- Boston, MA19 studi
- Cleveland, OH18 studi
- Minneapolis, MN17 studi
- Nashville, TN15 studi
- Philadelphia, PA14 studi
- San Francisco, CA14 studi
- Farmington Hills, MI13 studi
- Charleston, SC13 studi
- Chicago, IL13 studi
- Miami, FL13 studi
- Aurora, CO12 studi
Altri studi a New Haven
- Cancro del polmone non a piccole cellule41 studi
- Cancro al seno37 studi
- Cancro (tutti i tipi)33 studi
- Cancro metastatico23 studi
- Cancro ai polmoni22 studi
- Carcinoma a cellule squamose della testa e del collo22 studi
- Cancro ovarico21 studi
- Cancro colorettale20 studi
- Cancro alla prostata20 studi
- Overdose di oppioidi18 studi
- Disturbo da uso di alcol (AUD)17 studi
- Leucemia mieloide acuta17 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.